Lantheus Medical Imaging Announces Labeling Changes for DEFINITY®

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced important changes to the U.S. product label for DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension. DEFINITY® is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border1.

Back to news